Founder, Founders Fund · angel in 1 deal
Every published round Peter Thiel took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Varda Space Industries | Unnamed stage | 2025 | $187m | Participant | Forbes Australia |
Companies Peter Thiel has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Varda Space Industries | 2025 | 1 | 0 |
Fund closes reported for Peter Thiel, as distinct from the investments it has made.
Companies Peter Thiel has backed that another company then bought. An exit for the holding, not a deal Peter Thiel did.
Stories naming Peter Thiel. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Dealroom reports Australian battery materials startup Sicona acquired Louisiana-based Advano, taking its New Orleans facility, and recalls Advano's earlier $45 million raise backed by Tony Fadell and Peter Thiel.
Zac Altman’s ADHD telehealth startup Kantoko has secured $3.5 million in a Side Stage Ventures-led seed round, with Andrew Forrest’s Tenmile and Go1’s founders investing; the article also recalls his earlier ventures’ sales.
Also Dealroom·Startup Daily·Business News Australia·SmartCompany·ontargetish.com
Weekly roundup detailing eight trans-Tasman raises totalling A$373.3 million, headlined by Halter's Series E, spanning quantum computing, biomanufacturing, robotics, adtech and agtech, plus a recalled $2 billion founder exit.
Also Startup Daily
Halter, a New Zealand cattle-collar startup, has raised $220m in a Founders Fund-led Series E at a doubled $2bn valuation; the piece argues its ambitions reach beyond agtech.
Also AgFunderNews
Coverage of Andrew Tate's deplatforming and his shift to Rumble, which then topped the app charts; the piece also notes the video platform's backers and its earlier stated plan to list on Nasdaq.
Glyscend Therapeutics, a Johns Hopkins spin-out, is starting a Phase I trial of its type 2 diabetes pill in Adelaide; the piece recalls its AUD$29 million Series A led by Brandon Capital's MRCF.
Also Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio
Adelaide-backed biotech Glyscend is recruiting volunteers for phase 1 trials of a pill mimicking gastric bypass surgery to treat type 2 diabetes, funded with $29 million from Brandon Capital's MRCF, Santé Ventures and Breakout Labs.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio
Glyscend Therapeutics, an Adelaide-Baltimore biotech, is recruiting volunteers for phase 1 trials of GLY-200, a pill mimicking gastric bypass for type 2 diabetes, developed with $29 million from MRCF, Santé Ventures and Breakout Labs.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·Brandon Capital portfolio
Glyscend's diabetes pill has raised $29 million with backing from Brandon Capital, Santé Ventures and Breakout Labs, ahead of planned human trials in Adelaide.
Also Brandon Capital portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio
Microsoft commits a billion US dollars to OpenAI alongside a multi-year partnership to build AI super-computing on Azure, with OpenAI shifting services to the cloud platform.
Also tech-insider.org